23andMe and Genentech target Parkinson’s in deal up to $60 million

January 6, 2015 5:13 PM

1 0

Personal genetics-testing startup 23andMe is teaming up with Genentech to try to identify new treatments for Parkinson’s disease, the companies announced Tuesday in the first of several deals 23andMe is expected to strike with major pharmaceutical companies this year.

Under the deal, the South San Francisco biotech firm will sequence the whole genomes of about 3,000 people with Parkinson’s disease in 23andMe’s database and use that data to look for new therapeutic targets that could treat the neurodegenerative condition. The companies did not disclose financial t...

Also read: Yahoo Core Revenue Drops Again

Read more

To category page